Aeterna Zentaris (AEZS) Enters 10.4M ATM Offering

FREE Breaking News Alerts from StreetInsider.com!

More News related to AEZS

Aeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York
Aeterna Zentaris (AEZS) Updates on AEZS-108 Phase 1/2; Low Does Still Show Some Antitumor Acticity
Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco
Aeterna Zentaris (AEZS) Announces New At-the-Market Sales Agreement of Up 10.4 Million Shares

More News related to Corporate News

January 23, 2012 5:58 PM EST

Aeterna Zentaris Inc. (Nasdaq: AEZS) reports that, pursuant to its existing "At-the-Market" ("ATM") Sales Agreement, dated June 29, 2011, with MLV & Co. LLC ("MLV"), formerly McNicoll, Lewis & Vlak LLC, the Company is commencing a new ATM issuance program under which it may, at its discretion, from time to time during the term of the sales agreement, sell up to a maximum of 10,400,000 of its common shares through ATM issuances on the NASDAQ Stock Market up to an aggregate amount of US$16.0 million. MLV will act as sales agent for any sales made under the ATM. The common shares will be sold at market prices prevailing at the time of the sale of common shares, and, as a result, prices may vary.

Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market - FREE TRIAL!